#cbdinnovations

The global cannabidiol market is estimated to be valued at US$ 323.23 million in 2024 and is expected to exhibit a CAGR of 4% over the forecast period of 2023 to 2030. Key Takeaways Key players operating in the cannabidiol market are Geographically, the anesthesia gas evaporator market has been classified into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America hold the major share due to higher per capita income and technological advancement. Also, rise in health concerns among the people formed a major factor for rise in surgical and minimally invasive procedures in the U.S. According to American Society of Plastic Surgeons (ASPS), around 15.9 million surgical and minimally-invasive cosmetic procedures performed in the U.S. in 2015 which showed a 2% increase over 2014. The increasing legalization of cannabis and rising awareness about the therapeutic properties of CBD provide lucrative growth opportunities. Many countries and states have legalized the use of CBD products derived from hemp containing less than 0.3% of THC. Around 7.8 million Americans are estimated to have used legal CBD in 2020 according to Brightfield Group. Key companies are focusing on geographical expansion to penetrate developing regions having lenient CBD regulations such as Asia Pacific and Latin America. Companies are investing in new product development and acquisitions to consolidate their market share globally. Market Drivers Increasing legalization of cannabis derivatives: Legalization of cannabis and THC/CBD-containing hemp derivatives for medical and recreational adult use in various countries is expected to fuel the CBD market growth over the forecast period. This alleviates the restrictions over processing, distribution and retail of CBD-infused products. Awareness about therapeutic properties: With increased scientific research validating the therapeutic effects, consumers are gaining awareness about CBD’s benefits in easing symptoms of medical conditions such as epilepsy, multiple sclerosis and chronic pain. This drives its demand for both medical and wellness applications. Market Restraints Stringent regulations over CBD content: Distributors and manufacturers face challenges regarding varying regulations defining the maximum permissible levels of THC in CBD derivatives across different regions. Products violating these norms are at risk of facing legal consequences. Limited clinical evidence and research: More extensive clinical studies are still required to validate the therapeutic efficacy, safety, optimal dosage and potential drug interactions. This hinders the widespread adoption of CBD till now. Segment Analysis The cannabidiol market can be segmented based on product type into hemp-derived CBD and marijuana-derived CBD. Presently, the hemp-derived CBD segment dominates the market as it is legal in most parts of the world. Hemp-derived CBD is easily available, affordable, and has various therapeutic applications like reducing inflammation, pain, and anxiety. This wide demand and legal acceptance has made hemp-derived CBD the dominant segment currently. Global Analysis North America holds the largest share in the global cannabidiol market. Higher healthcare spending, presence of major players, and growing legal acceptance of marijuana drive the North America cannabidiol market. Within North America, the U.S. dominates due to presence of major companies and favorable laws allowing CBD products. The Asia Pacific region is expected to grow the fastest during the forecast period due to rising disposable incomes, growing health awareness, and relaxation of laws regarding CBD items in certain countries. China, India, Japan, and Australia are major markets in Asia Pacific supporting the regional growth of the cannabidiol industry. Rapidly developing healthcare sector also assists market expansion across Asia Pacific.